India’s First Dengue Vaccine in Final Trial Stage – May Be Available Within a Year

India has taken a big step towards fighting dengue fever, which affects lakhs of people every year during the rainy season. The country’s first indigenously developed dengue vaccine has reached its final clinical trial stage. If successful, the vaccine is expected to be available to the public within a year, according to health experts.

This vaccine, named TetraVax-DV, is being developed by the well-known Serum Institute of India (SII). It is designed to provide protection against all four types of dengue viruses. The Phase-3 clinical trials are currently being conducted in over 20 centers across the country. These trials began in 2023 and involve more than 10,000 volunteers, including both children and adults. The registration process for participants is almost complete.

Dengue is spread by the Aedes aegypti mosquito and causes severe fever, joint pain, and a drop in platelet count, which can be life-threatening. Scientists believe this new vaccine can help reduce dengue cases, hospitalizations, and deaths significantly. Medical teams are closely monitoring the health of the trial volunteers. If the trial results are positive, the vaccine may receive official approval from Indian health authorities soon.